版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
RabbitMonoclonalAntibodies--BetterToolsforBetterScience2022/11/221RabbitMonoclonalAntibodies20
AdvantagesofRabMAbTechnologyOverMouseMAbTechnologyHigherquality
HighaffinityandspecificityBroadapplicationsHighsuccessrateinmeetingcustomers’criteriaNovelEpitopesRecognitionofmouseorthologswithhighhomologyto humanantigensHigherthroughputStablehybridomasMultiplexHighhumanizationprobabilityHigherhomologytohumangermlinesequencethanmouseAinvitropositiveproof-of-conceptstudy2022/11/22AdvantagesofRabMAbTechnoloRabbitsRecognizeMoreEpitopesMouseRabbitMolecular-weightmarkerFibronectinProteasedigestedfibronectin123 1235miceand3rabbitsWesternAnalysisPolyseraImmunizedwithhumanfibronectin2022/11/22RabbitsRecognizeMoreEpitopeSupernatantFromRabbitHybridomaIsHighlyActiveInWesternblotABCD(A=1:5;B=1:50;C=1:500;D=1:1000)K8Anti-HumanKeratin8MAb2022/11/22SupernatantFromRabbitHybridARandomCollectionOfRabMAbsHaveExtremelyHighAffinitiesAntigen MAb Kon(1/M.sec) Koff(1/sec) Kd(M)ER EPIer39 2.58x105 2.45x10-3 9.5x10-9ER EPIer14 2.03x105 9.28x10-5 4.57x10-10ER EPIer26 1.72x105 3.37x10-5 2.19x10-10ER EPIer38 2.87x105 7.79x10-4 2.71x10-9PR EPIpr42 1.18x106 1.63x10-2 1.38x10-8PR EPIpr33 3.22x106 4.13x10-6 1.28x10-12PR EPIpr88 4.46x105 2.51x10-4 5.63x10-10C29 EPIc2902 7.61x104 2.88x10-3 3.78x10-8C29 EPIc2903 3.26x104 3.12x10-6 9.57x10-11C29 EPIc2905 1.36x105 4.96x10-4 3.65x10-9C29 EPIc2906 3.43x104 4.57x10-5 1.33x10-9
Herceptin Kd(M)= 5.0x10-9 $300MRituxan 8.0x10-9 $1.1BSynagis 1.0x10-9 $600MRemicade 2.0x10-10 $270M2022/11/22ARandomCollectionOfRabMAbsRabMAbForBetterDiagnosticsMouse1A6RabMAbHeattreateduntreated2022/11/22RabMAbForBetterDiagnosticsMRabbitMAbMouseMAbPhageMAbNonPrimaryAbRabMAb:MoreAccurateResults---ComparisonofrabbitMAb,mouseMAbandphageMAb50%falsepositive15%falsepositive5%falsepositive2022/11/22RabbitMAbMouseMAbPhageMAbNoFibrinDegradationProductsFibrin(Bloodclot)PlasminPlasminogenEndotheliaCellPAI-1tPA
PropertyApplicationtPARabMAb
clone8BindDiagnosticsclone15InhibitTherapeuticsclone22StimulateTherapeuticsclone29StrongstimulateTherapeuticsclone34BindDiagnostics
PAI-1RabMAb
clone2InhibitPAI-1/tPATherapeuticsclone7BindDiagnosticsclone10InhibitPAI-1/tPATherapeuticsclone12InhibitPAI-1/tPATherapeuticsclone14BindDiagnosticsOneProcess:MultipleRabMAbProductsPAI-1tPA2022/11/22FibrinFibrin(Bloodclot)PlasPathoMAbtoIdentifyTherapeuticMAbandDiseaseTargetTumorcellEmbryoniccellInflammatorytissueDegenerativetissueMembranefractionNuclearfraction…generatesupto10,000MAbsfromdiseasetissuesdirectly
YYYYYAntigensBioactivityTherapeuticMAbcandidatesDiseasetargetsCell-basedassays2022/11/22PathoMAbtoIdentifyTherapeutMAbsAgainstMouseMammaryTumorsRaisedFromASingleRabbit~7000hybridomaclonesgenerated: 157of1152antibodiesareusefulforimmunohistochemistry80antibodiespreferentiallyrecognizetumor 57antibodiesreactwithepitheliumcells 2antibodiesbindspecificfornecroticareasoftumor11antibodiesreactwithstroma 2antibodies staincell-celljunctions 5antibodies detectsecretedmolecules 10antibodiesreactwithmyoepithelialcells 2022/11/22MAbsAgainstMouseMammaryTumBlockingMAbsforTumorCellAdhesion2022/11/22BlockingMAbsforTumorCellAPrimarytumor(<20%expression)Lungmetastasis(100%expression)RabMAbToANovelIonChannelTumorAntigen
---
identifieddirectlyfromimmunizationofcancertissues2022/11/22Primarytumor(<20%expressionUsingSubtractivePathoMAbtoIdentifyMAbsSpecifictoDiseaseTissuesImmunizeRabbitwithLungCancerCellsScreenHybridomaAgainstLungCancerCellsBack-ScreenPositivesAgainstNormalLungCells100MAbs5MAbs2022/11/22UsingSubtractivePathoMAbtoAKidneySpecificAntibodyGeneratedbyPathoMAbBrainLungLiverKidney2022/11/22AKidneySpecificAntibodyGenProofOfPrincipleForHumanizedRabMAb---from75%to95%humansequence
HzdMAbRabMAb293b-6transfectants293untransfected2022/11/22ProofOfPrincipleForHumanizMarketDemandForRabMAbsSmallMoleculesPeptidesMTMProteinsMouseMAbsUnavailable-NovelResearchreagentsorleadsforresearch,drugdiscoveryanddiagnostics.MouseMAbsAvailable-Opportunityforbetterqualityfollow-onantibodiesHigherAffinityDiagnosticsNovelEpitopesHigherAffinitiesTherapeuticsAntibodyPairsResearchReagentAntibodyArrays2022/11/22MarketDemandForRabMAbsPeptiImproveTheProbabilityOfSuccessForDrugDiscoveryRabMAbTechnologyTargetID&ValidationProteinlevel,Clinical-directedtargetvalidationMultiplex,CompaniondiagnosticsNovelEpitope,HighaffinityTherapeuticleadsDiagnosticleads2022/11/22ImproveTheProbabilityOfSucSuccessRateOfRabMAbGeneration2022/11/22SuccessRateOfRabMAbGenerat
Customers2022/11/22
SummaryRabMAbisasuperiortechnologyplatformthatiswidelyacceptedbytheindustryEpitomicsenjoysrapidgrowthincustomersforresearch,diagnosticandtherapeuticfieldsRabbitMAbshavehighaffinity;Rabbithybridomasarestable;Thesuccessratetoobtain“desirable”MAbsishigh;Thethroughputcanbehigh.
2022/11/22SummaryRabMAbisasuperiorteRabbitMonoclonalAntibodies--BetterToolsforBetterScience2022/11/2221RabbitMonoclonalAntibodies20
AdvantagesofRabMAbTechnologyOverMouseMAbTechnologyHigherquality
HighaffinityandspecificityBroadapplicationsHighsuccessrateinmeetingcustomers’criteriaNovelEpitopesRecognitionofmouseorthologswithhighhomologyto humanantigensHigherthroughputStablehybridomasMultiplexHighhumanizationprobabilityHigherhomologytohumangermlinesequencethanmouseAinvitropositiveproof-of-conceptstudy2022/11/22AdvantagesofRabMAbTechnoloRabbitsRecognizeMoreEpitopesMouseRabbitMolecular-weightmarkerFibronectinProteasedigestedfibronectin123 1235miceand3rabbitsWesternAnalysisPolyseraImmunizedwithhumanfibronectin2022/11/22RabbitsRecognizeMoreEpitopeSupernatantFromRabbitHybridomaIsHighlyActiveInWesternblotABCD(A=1:5;B=1:50;C=1:500;D=1:1000)K8Anti-HumanKeratin8MAb2022/11/22SupernatantFromRabbitHybridARandomCollectionOfRabMAbsHaveExtremelyHighAffinitiesAntigen MAb Kon(1/M.sec) Koff(1/sec) Kd(M)ER EPIer39 2.58x105 2.45x10-3 9.5x10-9ER EPIer14 2.03x105 9.28x10-5 4.57x10-10ER EPIer26 1.72x105 3.37x10-5 2.19x10-10ER EPIer38 2.87x105 7.79x10-4 2.71x10-9PR EPIpr42 1.18x106 1.63x10-2 1.38x10-8PR EPIpr33 3.22x106 4.13x10-6 1.28x10-12PR EPIpr88 4.46x105 2.51x10-4 5.63x10-10C29 EPIc2902 7.61x104 2.88x10-3 3.78x10-8C29 EPIc2903 3.26x104 3.12x10-6 9.57x10-11C29 EPIc2905 1.36x105 4.96x10-4 3.65x10-9C29 EPIc2906 3.43x104 4.57x10-5 1.33x10-9
Herceptin Kd(M)= 5.0x10-9 $300MRituxan 8.0x10-9 $1.1BSynagis 1.0x10-9 $600MRemicade 2.0x10-10 $270M2022/11/22ARandomCollectionOfRabMAbsRabMAbForBetterDiagnosticsMouse1A6RabMAbHeattreateduntreated2022/11/22RabMAbForBetterDiagnosticsMRabbitMAbMouseMAbPhageMAbNonPrimaryAbRabMAb:MoreAccurateResults---ComparisonofrabbitMAb,mouseMAbandphageMAb50%falsepositive15%falsepositive5%falsepositive2022/11/22RabbitMAbMouseMAbPhageMAbNoFibrinDegradationProductsFibrin(Bloodclot)PlasminPlasminogenEndotheliaCellPAI-1tPA
PropertyApplicationtPARabMAb
clone8BindDiagnosticsclone15InhibitTherapeuticsclone22StimulateTherapeuticsclone29StrongstimulateTherapeuticsclone34BindDiagnostics
PAI-1RabMAb
clone2InhibitPAI-1/tPATherapeuticsclone7BindDiagnosticsclone10InhibitPAI-1/tPATherapeuticsclone12InhibitPAI-1/tPATherapeuticsclone14BindDiagnosticsOneProcess:MultipleRabMAbProductsPAI-1tPA2022/11/22FibrinFibrin(Bloodclot)PlasPathoMAbtoIdentifyTherapeuticMAbandDiseaseTargetTumorcellEmbryoniccellInflammatorytissueDegenerativetissueMembranefractionNuclearfraction…generatesupto10,000MAbsfromdiseasetissuesdirectly
YYYYYAntigensBioactivityTherapeuticMAbcandidatesDiseasetargetsCell-basedassays2022/11/22PathoMAbtoIdentifyTherapeutMAbsAgainstMouseMammaryTumorsRaisedFromASingleRabbit~7000hybridomaclonesgenerated: 157of1152antibodiesareusefulforimmunohistochemistry80antibodiespreferentiallyrecognizetumor 57antibodiesreactwithepitheliumcells 2antibodiesbindspecificfornecroticareasoftumor11antibodiesreactwithstroma 2antibodies staincell-celljunctions 5antibodies detectsecretedmolecules 10antibodiesreactwithmyoepithelialcells 2022/11/22MAbsAgainstMouseMammaryTumBlockingMAbsforTumorCellAdhesion2022/11/22BlockingMAbsforTumorCellAPrimarytumor(<20%expression)Lungmetastasis(100%expression)RabMAbToANovelIonChannelTumorAntigen
---
identifieddirectlyfromimmunizationofcancertissues2022/11/22Primarytumor(<20%expressionUsingSubtractivePathoMAbtoIdentifyMAbsSpecifictoDiseaseTissuesImmunizeRabbitwithLungCancerCellsScreenHybridomaAgainstLungCancerCellsBack-ScreenPositivesAgainstNormalLungCells100MAbs5MAbs2022/11/22UsingSubtractivePathoMAbtoAKidneySpecificAntibodyGeneratedbyPathoMAbBrainLungLiverKidney2022/11/22AKidneySpecificAntibodyGenProofOfPrincipleForHumanizedRabMAb---from75%to95%humansequence
HzdMAbRabMAb293b-6transfectants293untransfected2022/11/22ProofOfPrincipleForHumanizMarketDemandForRabMAbsSmallMoleculesPeptidesMTMProteinsMouseMAbsUnavailable-NovelResear
溫馨提示
- 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間，僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請(qǐng)與我們聯(lián)系，我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 課題申報(bào)參考：近代漢文中國行紀(jì)與全球文學(xué)關(guān)系研究
- 2025年度個(gè)人與公司租賃合同稅費(fèi)承擔(dān)協(xié)議4篇
- 二零二五版金融服務(wù)保密協(xié)議范本修訂6篇
- 2025年保定怎么考貨運(yùn)從業(yè)資格證
- 二零二五年城投小貸與農(nóng)業(yè)產(chǎn)業(yè)合作框架協(xié)議4篇
- 2025年度農(nóng)村土地流轉(zhuǎn)經(jīng)營權(quán)抵押貸款合同示范文本4篇
- 二零二五年度充電樁安裝工程知識(shí)產(chǎn)權(quán)保護(hù)合同4篇
- 二零二五年度出境領(lǐng)隊(duì)旅游目的地考察合同4篇
- 二零二五年度城市綜合體建設(shè)項(xiàng)目承包商安全作業(yè)管理協(xié)議4篇
- 2025年度葡萄采摘季節(jié)臨時(shí)工采購合同范本3篇
- 垃圾處理廠工程施工組織設(shè)計(jì)
- 天皰瘡患者護(hù)理
- 2025年蛇年新年金蛇賀歲金蛇狂舞春添彩玉樹臨風(fēng)福滿門模板
- 《建筑制圖及陰影透視（第2版）》課件 4-直線的投影
- 2024-2030年中國IVD（體外診斷）測(cè)試行業(yè)市場(chǎng)發(fā)展趨勢(shì)與前景展望戰(zhàn)略分析報(bào)告
- 損失補(bǔ)償申請(qǐng)書范文
- 壓力與浮力的原理解析
- 鐵路損傷圖譜PDF
- 裝修家庭風(fēng)水學(xué)入門基礎(chǔ)
- 移動(dòng)商務(wù)內(nèi)容運(yùn)營（吳洪貴）任務(wù)二 社群的種類與維護(hù)
- 《詩詞寫作常識(shí) 詩詞中國普及讀物 》讀書筆記思維導(dǎo)圖
評(píng)論
0/150
提交評(píng)論